+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis



Bactericidal/permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis



Current Infectious Disease Reports 3(5): 407-412



The 55-kD bactericidal/permeability-increasing protein (BPI) is a neutrophil-derived polypeptide belonging to a family of lipid and endotoxin binding proteins. BPI is composed of two functionally distinct structural domains: a potently antibacterial and antiendotoxin ∼ 20-kD aminoterminal half, and an opsonic carboxy-terminal portion. In multiple animal models, a recombinant amino-terminal fragment of BPI (rBPI21) is nontoxic and protects against gram-negative bacteria and endotoxin. In humans, rBPI21 is also nontoxic and nonimmunogenic and has undergone phase II/III clinical trials with apparent therapeutic benefit.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051750707

Download citation: RISBibTeXText

PMID: 24395478

DOI: 10.1007/s11908-007-1007-y


Related references

The bactericidal/permeability-increasing protein in antibacterial host-defense. Journal of Leukocyte Biology (SUPPL ): 16, 1997

The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. Journal of Leukocyte Biology 64(1): 14-18, 1998

Bactericidal/permeability increasing protein and host defense against gram-negative bacteria and endotoxin. Current Opinion in Immunology 5(1): 103-107, 1993

The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide. Immunobiology 187(3-5): 417-429, 1993

Bactericidal/Permeability-Increasing Protein Improves Survival During Immuno-Suppression-Related Bacterial Sepsis. Shock 3: 51-52, 1995

Recombinant bactericidal/permeability-increasing protein in the treatment of sepsis and gram-negative infections. Abstracts of Papers American Chemical Society 209(1-2): MEDI 146, 1995

A comparison of bactericidal/permeability-increasing protein variant versus recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in rats. Critical Care Medicine 25(1): 101-105, 1997

Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome. Intensive Care Medicine 26(9): 1248-1251, 2000

Bactericidal/permeability-increasing protein in sepsis correlates with the severity of sepsis and the outcome. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 378, 1999

Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Critical Care Medicine 29(3): 557-561, 2001

Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties. Journal of Infectious Diseases 170(6): 1473-1482, 1994

The role of lipopolysaccharide-binding protein and bactericidal/permeability-increasing protein in regulating host responses to bacterial lipopolysaccharide. Macvittie, T J, Weiss, J F, Browne, D Advances in the Biosciences; Advances in the treatment of radiation injuries 173-175, 1996

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. Lancet (North American Edition) 356(9234): 961-967, 2000

Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrobial Agents and ChemoTherapy 40(1): 65-69, 1996

Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflammatory Bowel Diseases 10(6): 763-770, 2005